{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:43:25Z","timestamp":1787010205278,"version":"build-2736575974"},"reference-count":53,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,12]]},"abstract":"<jats:sec>\n                    <jats:title>Purpose of review<\/jats:title>\n                    <jats:p>Food allergies are on the rise. Though allergen avoidance and management of acute reactions have been the backbone of therapy, complete avoidance and timely acute care is often not feasible. Food allergen immunotherapy (FAIT) is a novel and evolving treatment option intended to induce desensitization and potential sustained unresponsiveness (SU) to food allergens. This review addresses the methods, mechanisms, efficacy, and adverse effects of oral immunotherapy (OIT), sublingual immunotherapy (SLIT), and epicutaneous immunotherapy (EPIT) for food allergens in the published literature.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent findings<\/jats:title>\n                    <jats:p>Single FAIT has been most extensively studied in peanut, milk, and hen's egg allergic patients and has been successful in achieving desensitization in treated individuals through various modalities. Long-term data regarding SU is limited; however, current data suggests subsets of patients may be more likely to achieve SU compared to others. Other studies are actively assessing multifood AIT and novel FAIT protocols with adjunctive therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Food allergy constitutes a prevalent problem with far-reaching consequences. The emergence of FAIT may mitigate the burden of food allergy. Current evidence is promising for specific allergens and pediatric patient populations. Future studies are needed to further assess efficacy between different modalities of immunotherapy for food allergens across an age continuum.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mop.0000000000001272","type":"journal-article","created":{"date-parts":[[2023,7,7]],"date-time":"2023-07-07T10:00:31Z","timestamp":1688724031000},"page":"680-685","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Updates in food allergen immunotherapy"],"prefix":"10.1097","volume":"35","author":[{"given":"Vibha","family":"Szafron","sequence":"first","affiliation":[{"name":"Baylor College of Medicine, Department of Pediatrics, Division of Immunology, Allergy and Retrovirology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchit","family":"Rana","sequence":"additional","affiliation":[{"name":"B-Baylor College of Medicine, Department of Medicine, Section of Immunology, Allergy and Rheumatology"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Anvari","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Department of Pediatrics, Division of Immunology, Allergy and Retrovirology"},{"name":"Texas Children's Hospital, William T. Shearer Center for Human Immunobiology, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,7,7]]},"reference":[{"key":"R1-20250730","doi-asserted-by":"crossref","first-page":"e20181235","DOI":"10.1542\/peds.2018-1235","article-title":"The public health impact of parent-reported childhood food allergies in the United States","volume":"142","author":"Gupta","year":"2018","journal-title":"Pediatrics"},{"key":"R2-20250730","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1081-1206(10)60908-8","article-title":"The impact of food allergy on the daily activities of children and their families","volume":"96","author":"Bollinger","year":"2006","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R3-20250730","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/jamapediatrics.2013.2376","article-title":"The economic impact of childhood food allergy in the United States","volume":"167","author":"Gupta","year":"2013","journal-title":"JAMA Pediatr"},{"key":"R4-20250730","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.anai.2019.01.014","article-title":"Economic burden of food allergy: a systematic review","volume":"122","author":"Bilaver","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"R5-20250730","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1398-9995.2007.01451.x","article-title":"Specific immunotherapy has longterm preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study","volume":"62","author":"Jacobsen","year":"2007","journal-title":"Allergy"},{"key":"R6-20250730","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1067\/mai.2002.121317","article-title":"Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study)","volume":"109","author":"Moller","year":"2002","journal-title":"J Allergy Clin Immunol"},{"key":"R7-20250730","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1186\/1465-9921-6-153","article-title":"Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study","volume":"6","author":"Polosa","year":"2005","journal-title":"Respir Res"},{"key":"R8-20250730","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/j.1398-9995.2004.00537.x","article-title":"Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis","volume":"59","author":"Polosa","year":"2004","journal-title":"Allergy"},{"key":"R9-20250730","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jaci.2005.11.014","article-title":"Durham systemic reaction. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis","volume":"117","author":"Frew","year":"2006","journal-title":"J Allergy Clin Immunol"},{"key":"R10-20250730","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1056\/NEJM197807272990401","article-title":"A controlled trial of immunotherapy in insect hypersensitivity","volume":"299","author":"Hunt","year":"1978","journal-title":"N Engl J Med"},{"key":"R11-20250730","first-page":"47","article-title":"The nuts and bolts of food immunotherapy: the future of food allergy","volume":"5","author":"Anvari","year":"2018","journal-title":"Children (Basel)"},{"key":"R12-20250730","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1111\/all.15276","article-title":"Oral desensitization therapy for peanut allergy induces dynamic changes in peanut-specific immune responses","volume":"77","author":"Bajzik","year":"2022","journal-title":"Allergy"},{"key":"R13-20250730","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1812856","article-title":"AR101 oral immunotherapy for peanut allergy","volume":"379","author":"Vickery","year":"2018","journal-title":"N Engl J Med"},{"key":"R14-20250730","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/S2352-4642(20)30234-0","article-title":"Efficacy and safety of oral immunotherapy with AR101 in European children with a peanut allergy (ARTEMIS): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial","volume":"4","author":"Hourihane","year":"2020","journal-title":"Lancet Child Adolesc Health"},{"key":"R15-20250730","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jaci.2016.05.027","article-title":"Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective","volume":"139","author":"Vickery","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"R16-20250730","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0140-6736(21)02390-4","article-title":"Efficacy and safety of oral immunotherapy in children aged 1\u20133\u200ayears with peanut allergy (the Immune Tolerance Network IMPACT trial): a randomised placebo-controlled study","volume":"399","author":"Jones","year":"2022","journal-title":"Lancet"},{"key":"R17-20250730","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/j.1365-2222.2011.03948.x","article-title":"Oral immunotherapy for IgE-mediated cow's milk allergy: a systematic review and meta-analysis","volume":"42","author":"Bro\u017cek","year":"2012","journal-title":"Clin Exp Allergy"},{"key":"R18-20250730","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1016\/j.jaci.2021.10.023","article-title":"Efficacy and safety of baked milk oral immunotherapy in children with severe milk allergy: A randomized, double-blind, placebo-controlled phase 2 trial","volume":"149","author":"Dantzer","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"R19-20250730","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1056\/NEJMoa1200435","article-title":"Oral immunotherapy for treatment of egg allergy in children","volume":"367","author":"Burks","year":"2012","journal-title":"N Engl J Med"},{"key":"R20-20250730","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1111\/pai.13437","article-title":"Evaluation of baked egg oral immunotherapy in French children with hen's egg allergy","volume":"32","author":"Gruzelle","year":"2021","journal-title":"Pediatr Allergy Immunol"},{"key":"R21-20250730","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S2352-4642(19)30029-X","article-title":"Walnut oral immunotherapy for desensitisation of walnut and additional tree nut allergies (Nut CRACKER): a single-centre, prospective cohort study","volume":"3","author":"Elizur","year":"2019","journal-title":"Lancet Child Adolesc Health"},{"key":"R22-20250730","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1111\/all.15212","article-title":"Cashew oral immunotherapy for desensitizing cashew-pistachio allergy (NUT CRACKER study)","volume":"77","author":"Elizur","year":"2022","journal-title":"Allergy"},{"key":"R23-20250730","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jaci.2018.08.041","article-title":"Multicenter, randomized, double-blind, placebo-controlled clinical trial of vital wheat gluten oral immunotherapy","volume":"143","author":"Nowak-W\u0119grzyn","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R24-20250730","doi-asserted-by":"crossref","first-page":"2775","DOI":"10.1016\/j.jaip.2019.05.031","article-title":"Efficacy and safety of sesame oral immunotherapy \u2013 a real-world, single-center study","volume":"7","author":"Nachshon","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R25-20250730","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1016\/S0140-6736(19)31793-3","article-title":"Sustained outcomes in oral immunotherapy for peanut allergy (POISED study): a large, randomised, double-blind, placebo-controlled, phase 2 study","volume":"394","author":"Chinthrajah","year":"2019","journal-title":"Lancet"},{"key":"R26-20250730","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/S2352-4642(22)00006-2","article-title":"Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial","volume":"6","author":"Loke","year":"2022","journal-title":"Lancet Child Adolesc Health"},{"key":"R27-20250730","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1016\/j.jaip.2020.12.029","article-title":"Continuous and daily oral immunotherapy for peanut allergy: results from a 2-year open-label follow-on study","volume":"9","author":"Vickery","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R28-20250730","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.jaci.2015.12.1316","article-title":"Long-term treatment with egg oral immunotherapy enhances sustained unresponsiveness that persists after cessation of therapy","volume":"137","author":"Jones","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"R29-20250730","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(19)30420-9","article-title":"Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety","volume":"393","author":"Chu","year":"2019","journal-title":"Lancet"},{"key":"R30-20250730","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/all.13319","article-title":"EAACI guidelines on allergen immunotherapy: IgE-mediated food allergy","volume":"73","author":"Pajno","year":"2018","journal-title":"Allergy"},{"key":"R31-20250730","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1016\/j.jaci.2019.06.038","article-title":"Effect of sleep deprivation and exercise on reaction threshold in adults with peanut allergy: A randomized controlled study","volume":"144","author":"Dua","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R32-20250730","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.jaip.2022.11.010","article-title":"Treatment of oral immunotherapy-associated eosinophilic esophagitis","volume":"11","author":"Epstein-Rigbi","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R33-20250730","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1097\/MPG.0000000000003631","article-title":"Oral immunotherapy and risk of eosinophilic esophagitis in children: 15 years\u2019 experience","volume":"76","author":"Morales-Cabeza","year":"2023","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R34-20250730","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.jaip.2022.11.036","article-title":"Omalizumab in IgE-mediated food allergy: a systematic review and meta-analysis","volume":"11","author":"Zuberbier","year":"2023","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R35-20250730","doi-asserted-by":"crossref","first-page":"921","DOI":"10.2217\/imt-2020-0123","article-title":"Sublingual immunotherapy for food allergy and its future directions","volume":"12","author":"Schworer","year":"2020","journal-title":"Immunotherapy"},{"key":"R36-20250730","first-page":"CD010638","article-title":"Oral and sublingual immunotherapy for egg allergy","volume":"4","author":"Romantsik","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"R37-20250730","first-page":"514","article-title":"Sublingual immunotherapy in peach allergy: monitoring molecular sensitizations and reactivity to apple fruit and Platanus pollen","volume":"20","author":"Garc\u00eda","year":"2010","journal-title":"J Investig Allergol Clin Immunol"},{"key":"R38-20250730","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1111\/j.1398-9995.2006.01196.x","article-title":"Sublingual immunotherapy for cow's milk protein allergy: a preliminary report","volume":"61","author":"De Boissieu","year":"2006","journal-title":"Allergy"},{"key":"R39-20250730","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jaci.2005.08.027","article-title":"Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract","volume":"116","author":"Enrique","year":"2005","journal-title":"J Allergy Clin Immunol"},{"key":"R40-20250730","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jaci.2012.11.011","article-title":"Sublingual immunotherapy for peanut allergy: a randomized, double-blind, placebo-controlled multicenter trial","volume":"131","author":"Fleischer","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"R41-20250730","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/j.jaci.2014.12.1917","article-title":"Sublingual immunotherapy for peanut allergy: long-term follow-up of a randomized multicenter trial","volume":"135","author":"Burks","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"R42-20250730","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.jaci.2019.07.030","article-title":"Long-term sublingual immunotherapy for peanut allergy in children: clinical and immunologic evidence of desensitization","volume":"144","author":"Kim","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"R43-20250730","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jaci.2023.01.036","article-title":"Open-label study of the efficacy, safety, and durability of peanut sublingual immunotherapy in peanut-allergic children","volume":"151","author":"Kim","year":"2023","journal-title":"J Allergy Clin Immunol"},{"key":"R44-20250730","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jaip.2016.06.020","article-title":"Local side effects of sublingual and oral immunotherapy","volume":"5","author":"Passalacqua","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"key":"R45-20250730","doi-asserted-by":"crossref","first-page":"660974","DOI":"10.3389\/fimmu.2021.660974","article-title":"The role of regulatory T cells in epicutaneous immunotherapy for food allergy","volume":"12","author":"Liu","year":"2021","journal-title":"Front Immunol"},{"key":"R46-20250730","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1016\/j.jaci.2020.11.027","article-title":"Epicutaneous immunotherapy for treatment of peanut allergy: follow-up from the Consortium for Food Allergy Research","volume":"147","author":"Scurlock","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"R47-20250730","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1001\/jama.2019.1113","article-title":"Effect of epicutaneous immunotherapy vs placebo on reaction to peanut protein ingestion among children with peanut allergy: the PEPITES Randomized Clinical Trial","volume":"321","author":"Fleischer","year":"2019","journal-title":"JAMA"},{"key":"R48-20250730","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.jaci.2020.06.028","article-title":"Long-term, open-label extension study of the efficacy and safety of epicutaneous immunotherapy for peanut allergy in children: PEOPLE 3-year results","volume":"146","author":"Fleischer","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"R49-20250730","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1056\/NEJMoa2212895","article-title":"Phase 3 trial of epicutaneous immunotherapy in toddlers with peanut allergy","volume":"388","author":"Greenhawt","year":"2023","journal-title":"N Engl J Med"},{"issue":"(Suppl)","key":"R50-20250730","doi-asserted-by":"crossref","first-page":"AB132","DOI":"10.1016\/j.jaci.2015.12.566","article-title":"Safety of viaskin milk epicutaneous immunotherapy (EPIT) in IgE-mediated cow's milk allergy (CMA) in children (MILES study)","volume":"137","author":"Rutault","year":"2016","journal-title":"J Allergy Clin Immunol"},{"key":"R51-20250730","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11095-019-2728-y","article-title":"Immunogenicity of milk protein-containing hydrophilic gel patch for epicutaneous immunotherapy for milk allergy","volume":"37","author":"Ito","year":"2020","journal-title":"Pharm Res"},{"key":"R52-20250730","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1016\/j.jaci.2010.02.029","article-title":"Cow's milk epicutaneous immunotherapy in children: a pilot trial of safety, acceptability, and impact on allergic reactivity","volume":"125","author":"Dupont","year":"2010","journal-title":"J Allergy Clin Immunol"},{"key":"R53-20250730","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.jaip.2021.11.017","article-title":"Safety of epicutaneous immunotherapy in peanut-allergic children: REALISE Randomized Clinical Trial Results","volume":"10","author":"Pongracic","year":"2022","journal-title":"J Allergy Clin Immunol Pract"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001272","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T18:01:05Z","timestamp":1753898465000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,7]]},"references-count":53,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001272","relation":{},"ISSN":["1040-8703","1531-698X"],"issn-type":[{"value":"1040-8703","type":"print"},{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,7]]}}}